GlaxoSmithKline (NYSE:GSK): Closing price $44.28
On Wednesday, GlaxoSmithKline and Theravance (NASDAQ:THRX) reported the submission of a regulatory application in the European Union for the investigational once-daily LAMA/LABA combination medicine, UMEC/VI, for patients suffering from chronic obstructive pulmonary disease . On December 18th, the firm announced the submission of a regulatory application with the FDA for UMEC/VI.
Don't miss one of the biggest bull markets in history! Covers Gold, Silver, Gold & Silver stocks, and miners.
Learn More
There's always a bull market in some sector! Find the best opportunities in commodities.
Learn more
At last, a trading system that buys the right ETFs at the right time, time after time!
Learn more